Search
Research
Improving Wellbeing for Young People Living with Rheumatic Heart Disease: A peer support program through Danila Dilba Health ServiceThis project seeks to conduct a focus group for young people (aged 11-14) and their parents/family members through the Danila Dilba Health Service (DDHS) in Darwin with the aim of identifying consumer needs and perspectives on next steps and priorities for peer support in RHD.
Research
Interventions to eliminate rheumatic heart diseaseFunded by a 5-year NHMRC Investigator grant to implement a strategy to eliminate rheumatic heart disease (RHD) as a public health problem in Australia.
Research
RHD Screening Program - GE HealthcareThis project aims to empower local clinicians with skills and knowledge of using handheld echocardiography (HAND) that will allow for mobile service provision into remote Indigenous communities.
Research
Skin health situational analysis to inform skin disease control programs for the KimberleyThe aim of this project is to conduct a situational analysis of the skin health services and activities currently available for managing skin infections within the Kimberley.
Research
Australian Strep A Vaccine Initiative (ASAVI)The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.
Research
Penicillin Levels for Rheumatic Heart Disease Study – Remote CohortAsha Jonathan Bowen Carapetis AM BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS Head, Healthy Skin and ARF Prevention Executive
Research
What risk does underlying trimethoprim resistance pose for the development of cotrimoxazole-resistant skin infectionsInvestigating what risk does underlying trimethoprim resistance pose for the development of cotrimoxazole-resistant skin infections.
Research
A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of ageJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 yearsJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
UVR exposure, Vitamin D and type 1 diabetesLiz Prue Davis Hart MBBS FRACP PhD BSc (Hons) MSc PhD Co-director of Children’s Diabetes Centre Honorary Research Fellow prue.hart@thekids.org.au